Clinical trials: Cancer, Gastrointestinal
Gastrointestinal Stromal Tumors
Efficacy and Safety of Nilotinib (AMN107) Compared With Current Treatment Options in Patients With GIST Who Have Failed Both Imatinib and Sunitinib
The study evaluated the safety and efficacy of nilotinib versus current treatment in adults with gastrointestinal stromal tumors (GIST) who have either progressed or who were intolerant to the first and second line treatments.
- Trial name
- ENEST (NCT00471328)
- Testing
- Nilotinib, Best Supportive Care (BSC) +/- imatinib or sunitinib
- Where
- 35 sites in United States, Australia and 11 more
- Volunteers
- 248 people
- Sponsor
- Novartis Pharmaceuticals
Solid Tumors
A Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat, With or Without Pembrolizumab, in Advanced Solid Tumors
The purpose of this study is to assess the safety and antitumor activity of INCB001158 plus epacadostat, with or without pembrolizumab, in participants with advanced or metastatic solid tumors.
- Trial name
- NCT03361228
- Testing
- INCB001158, Epacadostat, Pembrolizumab
- Where
- 2 sites in United States
- Volunteers
- 5 people
- Sponsor
- Incyte Corporation
Age-Related Macular Degeneration, Allergies
Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
To collect, preserve, and/or distribute annotated biospecimens and associated medical data to institutionally approved, investigator-directed biomedical research to discover and develop new treatments, diagnostics, and…
- Conditions
- Age-Related Macular Degeneration, Allergies, Alpha-Gal Syndrome, Alzheimer Disease
- Trial name
- NCT05635266
- Testing
- Specimen sample
- Where
- United States
- Volunteers
- 20,000 people, healthy volunteers welcome
- Sponsor
- Sanguine Biosciences
Advanced Solid Tumor, Gastric Cancer (GC)
Study of SYSA1801 in the Treatment of Claudin( CLDN) 18.2 Positive Advanced Malignant Solid Tumor
This is an open-label, dose escalation, dose expansion and extension cohort phase 1 study to evaluate the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of SYSA1801
- Conditions
- Advanced Solid Tumor, Gastric Cancer (GC), Gastroesophageal Junction (GEJ) Cancer, Pancreatic Cancer
- Trial name
- NCT05009966
- Testing
- SYSA1801 for injection
- Where
- China
- Volunteers
- 272 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Nausea and Vomiting, Chemotherapy-Induced
A Study Of IV Casopitant For The Prevention Of Chemotherapy Induced Nausea And Vomiting.
This a Phase III trial designed to determine if IV casopitant plus dexamethasone and ondansetron is more effective in the prevention of vomiting and nausea then dexamethasone and ondansetrone alone following the administration of…
- Trial name
- NCT00601172
- Testing
- Casopitant, Dexamethasone, Ondansetron
- Where
- 96 sites in United States, Belgium and 9 more
- Volunteers
- 710 people
- Sponsor
- GlaxoSmithKline
Colorectal Cancer
Nitrocamptothecin in Treating Patients With Advanced or Recurrent Colorectal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of nitrocamptothecin in treating patients who have…
- Trial name
- NCT00005877
- Testing
- rubitecan
- Where
- United States
- Sponsor
- Astex Pharmaceuticals, Inc.
Colorectal Cancer
A Phase 1 Study of OCV-C02 in Patients With Advanced or Relapsed Colorectal Cancer
To assess the safety and tolerability of OCV-C02 in Patients With Advanced or Relapsed Colorectal Cancer Who Are Refractory or Intolerant to Standard Chemotherapy
- Trial name
- NCT01801930
- Testing
- OCV-103 and OCV-104
- Where
- 3 sites in Japan
- Volunteers
- 24 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Advanced Renal Cell Carcinoma, Gastrointestinal Stromal Tumors
Dose-Escalation Study of TH-302 in Combination With Sunitinib to Treat Patients With Advanced Renal Cell Carcinoma,Gastrointestinal Stromal Tumors and Pancreatic Neuroendocrine Tumors
The primary objectives are: Dose escalation: 1. To determine the MTD and DLT(s) of TH-302 when used in combination with sunitinib. Dose expansion: 1.
- Conditions
- Advanced Renal Cell Carcinoma, Gastrointestinal Stromal Tumors, Pancreatic Neuroendocrine Tumors
- Trial name
- TH-CR-410 (NCT01381822)
- Testing
- TH-302
- Where
- 2 sites in United States
- Volunteers
- 58 people
- Sponsor
- Threshold Pharmaceuticals
HER-2 Gene Amplification, HER2-positive Gastric Cancer
Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) in Subjects With HER2-Positive Solid Tumors
This is a Phase 1/2, open-label, multicenter, non-randomized study to investigate the safety, tolerability, and clinical activity of HER2-specific dual-switch CAR-T cells, BPX-603, administered with rimiducid to subjects with…
- Conditions
- HER-2 Gene Amplification, HER2-positive Gastric Cancer, HER2-positive Breast Cancer, HER-2 Protein Overexpression
- Trial name
- NCT04650451
- Testing
- chimeric antigen receptor (CAR) T cell therapy
- Where
- 7 sites in United States
- Volunteers
- 220 people
- Sponsor
- Bellicum Pharmaceuticals
Solid Tumours, Sarcoma
A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors
The purpose of this study is to investigate the study drug, OKN4395, administered alone and in combination with pembrolizumab. The overall objectives of this study are to determine the safety and tolerability (degree to which…
- Conditions
- Solid Tumours, Sarcoma, HNSCC, Non Small Cell Lung Cancer
- Trial name
- INVOKE (NCT06789172)
- Testing
- OKN4395, Pembrolizumab, Fasting
- Where
- 10 sites in United States, Australia and 1 more
- Volunteers
- 146 people
- Sponsor
- Epkin
Breast Neoplasms, Colorectal Neoplasms
Phase 1 Dose Escalation Study of SN2310 Injectable Emulsion in Patients With Advanced Solid Tumors
This is a Phase 1 open-label study of SN2310 Injectable Emulsion in patients with advanced solid malignancies. The study is designed to determine the maximum tolerated dose and dose-limiting toxicity of SN2310 Injectable…
- Conditions
- Breast Neoplasms, Colorectal Neoplasms, Pancreatic Neoplasms, Pelvic Neoplasms
- Trial name
- NCT00385177
- Testing
- SN2310 Injectable Emulsion
- Where
- 2 sites in United States
- Volunteers
- 61 people
- Sponsor
- Achieve Life Sciences
Hepatocellular Carcinoma
Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.
The primary objective of this study was to evaluate the efficacy of anlotinib hydrochloride capsules combined with penpulimab injection (test group) versus placebo (control group) for adjuvant therapy after radical surgery or…
- Trial name
- NCT05862337
- Testing
- Anlotinib hydrochloride capsules, Penpulimab injection
- Where
- 67 sites in China
- Volunteers
- 480 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
A Study of Ramucirumab (LY3009806) in Combination With Paclitaxel in Participants With Gastric Cancer
The main purpose of this study is to evaluate the efficacy of an alternative dose of ramucirumab in combination with paclitaxel in participants with second-line metastatic or locally advanced, unresectable gastric or…
- Trial name
- NCT02514551
- Testing
- Ramucirumab, Paclitaxel
- Where
- 52 sites in United States, Belgium and 9 more
- Volunteers
- 245 people
- Sponsor
- Eli Lilly and Company
Stomach Neoplasms
A Phase 1/2 Study Evaluating AMG 337 in Asian Subjects
This is a multicenter, Phase 1/2 study. The study will evaluate the tolerability, safety and activity of AMG 337 in Asian subjects who have advanced solid tumors (Phase 1) or subjects with MET amplified tumors with a focus on…
- Trial name
- NCT02096666
- Testing
- AMG 337
- Where
- 4 sites in Japan
- Volunteers
- 11 people
- Sponsor
- Amgen
Gastric Low-grade MALT Lymphoma With Helicobacter Pylori Positive
Prognostic Study of Gastric MALT Lymphoma After Eradication of Helicobacter Pylori
To survey the grade of gastric MALT lymphoma after eradication of Helicobacter pylori
- Trial name
- NCT01264822
- Testing
- Rabeprazole Sodium
- Where
- 42 sites in Japan
- Volunteers
- 108 people
- Sponsor
- Eisai Co., Ltd.
Hepatocellular Carcinoma (HCC), Solid Malignancies
FGF401 in HCC and Solid Tumors Characterized by Positive FGFR4 and KLB Expression
Estimate the maximum tolerated dose and/or recommended phase II dose and efficacy of FGF401 as single agent and in combination with PDR001 in patients with hepatocellular carcinoma and as single agent in patients with other solid…
- Trial name
- NCT02325739
- Testing
- FGF401, PDR001
- Where
- 27 sites in United States, China and 9 more
- Volunteers
- 172 people
- Sponsor
- Novartis Pharmaceuticals
Pancreatic Cancer
An Open, Single-center Study to Determine the Antibody Repsonse to Gastrimmune and Its Safety and Tolerability in Patients With Advanced Pancreatic Carcinoma
This study was designed to determine the effect of jaundice on the ability of G17DT to generate antibodies before and after treatment of biliary obstruction due to advanced pancreatic cancer.
- Trial name
- PC1 (NCT02098291)
- Testing
- G17DT
- Volunteers
- 34 people
- Sponsor
- Cancer Advances Inc.
Colorectal Neoplasms
Study With AG-013736 Combined With Chemotherapy And Bevacizumab In Patients With Metastatic Colorectal Cancer
To determine the safety and efficacy of AG-013736 in combination with other standard of care medication in patients with first line metastatic colorectal cancer.
- Trial name
- NCT00460603
- Testing
- bevacizumab, AG-013726, AG-013736 (axitinib)
- Where
- 106 sites in United States
- Volunteers
- 187 people
- Sponsor
- Pfizer
Colorectal Cancer, Head and Neck Cancer
Combination Study of BMS-754807 and Erbitux® in Subjects With Advanced or Metastatic Solid Tumors
The study is expected to identify a safe dose of BMS-754807 to be given in combination with a standard dose of cetuximab and the recommended dose or dose range for Phase II studies.
- Conditions
- Colorectal Cancer, Head and Neck Cancer, Neoplasm Metastasis
- Trial name
- NCT00908024
- Testing
- BMS-754807, cetuximab (Erbitux®)
- Where
- 5 sites in United States, Canada
- Volunteers
- 54 people
- Sponsor
- Bristol-Myers Squibb
Colonic Neoplasms
Metabiomics Colon Cancer Clinical Research Study
The specific aim of the study is to determine the false negative rate of the Metabiomics Colon Polyp and Colorectal Cancer Assay for Cancer.
- Trial name
- NCT02151123
- Where
- United States
- Sponsor
- Metabiomics Corp
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.